On April 25, 2024, NeuroSense Therapeutics Ltd., closed the transaction. The transaction included participation from single investor. As a part of the transaction, the company paid CAD 50,000 cash fee and 70,964 of the ordinary shares of the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.08 USD | -3.57% |
|
+27.77% | +37.58% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.58% | 19.48M | |
+15.82% | 122B | |
+20.35% | 114B | |
+17.47% | 25.71B | |
-25.31% | 19.02B | |
-19.51% | 15.83B | |
-19.67% | 15.32B | |
-46.87% | 14.88B | |
+62.55% | 14.82B | |
+6.34% | 14.1B |
- Stock Market
- Equities
- NRSN Stock
- News NeuroSense Therapeutics Ltd.
- NeuroSense Therapeutics Ltd. announced that it has received $4.47 million in funding